Clinical trial
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
NCT00066703 is registered in ClinicalTrials.gov with ETOP IBCSG Partners Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 3, 2003
- Completion date
- October 23, 2024
- Enrollment
- 2,672 (actual)
- Sites
- 228
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer